Pharvaris (PHVS) Share-based Compensation Growth (3y) (2023 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Share-based Compensation Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 17.49% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 9.95% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 4.55% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 30.98% |
| 10 | Pharvaris | 2.15 Bn | 1.78 Bn | 85,072.10 | -98.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -98.90% |
| Mar 31, 2026 | 27.41% |
| Dec 31, 2025 | 17.21% |
| Sep 30, 2025 | 25.99% |
| Jun 30, 2025 | -98.95% |
| Mar 31, 2025 | 25.72% |
| Dec 31, 2024 | 31.47% |
| Sep 30, 2024 | -13,480.69% |
| Jun 30, 2024 | 14,593.04% |
| Mar 31, 2024 | 1.03% |
| Dec 31, 2023 | -98.88% |
| Sep 30, 2023 | -23,203.50% |
| Jun 30, 2023 | 24,171.99% |
| Mar 31, 2023 | 104.48% |